 |
| |
|
¿¡½ºÄÉÀ̼¼Æ÷Ƽ¾Ï±ÙÁÖ0.5g SK CEFOTIAM INTRAMUSCULAR INJ. 0.5g
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A18905961]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1º´(2008.07.01)(ÇöÀç¾à°¡)
\4,368 ¿ø/1º´(2008.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö ³»Áö ´ãȲ»öÀÇ ºÐ¸»Á¦·Î¼ ³¿»õ´Â ¾ø°Å³ª ¾à°£ ƯÀÌÇÑ ³¿»õ°¡ ÀÖ´Ù. [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾
Æ÷µµ±¸±Õ, ¿¬¼â±¸±Õ(Àå³»±¸±Õ Á¦¿Ü), Æó·Å¿¬¼â±¸±Õ, ÀÎÇ÷翣ÀÚ±Õ, ´ëÀå±Õ, Ŭ·¹ºê½Ã¿¤¶ó, ¿£Å׷ιÚÅÍ, ½ÃÆ®·Î¹ÚÅÍ, ÇÁ·ÎÅ׿콺 ¹Ì¶óºô¸®½º, ÇÁ·ÎÅ׿콺 ºÒ°¡¸®½º, ÇÁ·ÎÅ׿콺 ÇÁ·Îºñµ§½Ã¾Æ ·¹Æ®°Ô¸®, ¸ð¸£°¡³Ú¶ó ¸ð¸£°¡´Ï
¡Û ÀûÀÀÁõ
- ÆÐÇ÷Áõ
- ¼ö¼ú ÈÄ Ã¢»ó, È»ó ÈÄ °¨¿°
- ÇÇÇϳó¾ç, ¿ËÁ¾, Á¾±â, Á¾±âÁõ
- °ñ¼ö¿°, È³ó¼º °üÀý¿°
- Æíµµ¿°(ÆíµµÁÖÀ§¿°, ÆíµµÁÖÀ§³ó¾ç), ±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ(°¨¿° ½Ã), Æó·Å, Æó³ó¾ç, ³óÈä
- ´ã°ü¿°, ´ã³¶¿°
- º¹¸·¿°
- ½Å¿ì½Å¿°, ¹æ±¤¿°, ¿äµµ¿°, Àü¸³¼±¿°
- ¼ö¸·¿°
- Àڱó» °¨¿°, °ñ¹Ý»ç°¿°, ÀÚ±ÃÁÖÀ§Á¶Á÷¿°, Àڱúμӱ⿰, ¹ÙÅ丰¼±¿°
- ÁßÀÌ¿°, ºÎºñµ¿¿°
(Çdz»¹ÝÀÀ¿ë)
ÀÌ ¾à¹°ÀÇ ±ÙÀ°ÁÖ»ç ¹× Á¤¸ÆÁÖ»ç Åõ¿© ½Ã Çdz»¹ÝÀÀ¿¡ »ç¿ëÇÑ´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1. Á¤¸ÆÁÖ»ç
¡Û ¼ºÀÎ : ¼¼Æ÷Ƽ¾ÏÀ¸·Î¼ 1ÀÏ 0.5¢¦2g(¿ª°¡)À» 2¢¦4ȸ ºÐÇÒ Á¤¸ÆÁÖ»ç ÇÑ´Ù.
¡Û ¼Ò¾Æ : 1ÀÏ Ã¼Áß Kg´ç 40¢¦80mg(¿ª°¡)À» 3¢¦4ȸ ºÐÇÒ Á¤¸ÆÁÖ»ç ÇÑ´Ù.
¡Û ¼ºÀÎÀÇ ÆÐÇ÷Áõ¿¡´Â 1ÀÏ 4g(¿ª°¡)±îÁö, ¼Ò¾ÆÀÇ ÆÐÇ÷Áõ, ¼ö¸·¿° µîÀÇ ÁßÁõ ¹× ³Ä¡¼º °¨¿°Áõ¿¡´Â 1ÀÏ Ã¼Áß Kg´ç 160mg(¿ª°¡)±îÁö Áõ·®ÇÒ ¼ö ÀÖ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
<ÁÖ»ç¾×ÀÇ Á¶Á¦¹ý>
Á¤¸ÆÁÖ»ç ½Ã´Â ÁÖ»ç¿ë¼ö, »ý¸®½Ä¿°ÁÖ»ç¾× ¶Ç´Â 5% Æ÷µµ´ç ÁÖ»ç¾×¿¡ ³ì¿© ÁÖ»çÇÑ´Ù.
Á¡Àû Á¤¸ÆÁÖ»ç ½Ã´Â 1ȸ·® 0.25¢¦2g(¿ª°¡)À» ´ç¾×, ÀüÇØÁú¾× ¶Ç´Â ¾Æ¹Ì³ë»ê Á¦Á¦ µîÀÇ º¸¾×¿¡ ³ì¿© 30ºÐ¢¦2½Ã°£¿¡ °ÉÃÄ Á¡Àû Á¤¸ÆÁÖ»çÇϰí, ¼Ò¾ÆÀÇ °æ¿ì¿¡´Â À§ÀÇ Åõ¿©·®À» °í·ÁÇÏ¿© 30ºÐ¢¦1½Ã°£¿¡ °ÉÃÄ Åõ¿©Ç쵂 ³ìÀÏ ¶§ ÁÖ»ç¿ë¼ö´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù(µîÀå¾×ÀÌ ¾Æ´Ô.).
2. ±ÙÀ°ÁÖ»ç
¡Û ¼ºÀÎ : ¼¼Æ÷Ƽ¾ÏÀ¸·Î¼ 1ÀÏ 0.5¢¦2g(¿ª°¡)À» 2¢¦4ȸ ºÐÇÒ ±ÙÀ°ÁÖ»ç ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
<ÁÖ»ç¾×ÀÇ Á¶Á¦¹ý>
1 ¹ÙÀÌ¾Ë ´ç ÷ºÎµÈ ±ÙÀ°ÁÖ»ç¿ë ¿ëÇØ¾× 3mL·Î ³ì¿© »ç¿ëÇÑ´Ù.
(Çdz»¹ÝÀÀ¿ë)
ÀÌ ¾àÀ» ÁÖ»ç¿ë¼ö 1mL·Î ¿ëÇØ½ÃÄÑ 300§¶/mLÀÇ ½ÃÇè¾×À» Á¶Á¦ÇÑ´Ù. ÀÌ ½ÃÇè¾× ¾à 0.02mL¸¦ Çdz» ÁÖ»çÇÑ´Ù. ¶Ç ´ëÁ¶·Î¼ »ý¸®½Ä¿°ÁÖ»ç¾× ¾à 0.02mL¸¦ ½ÃÇè¾× ÁÖ»çºÎÀ§·ÎºÎÅÍ ÃæºÐÈ÷ ¶³¾îÁø À§Ä¡¿¡ Çdz»ÁÖ»ç ÇÑ´Ù.
<ÆÇÁ¤¹æ¹ý>
½ÃÇè¾× ¹× ´ëÁ¶¾× ¸ðµÎ Çdz»ÁÖ»ç(Åõº£¸£Äð¸°ÁÖ»ç±â¸¦ »ç¿ëÇÔ.)Çϰí 15¢¦30ºÐ ÈÄ¿¡ ÁÖ»çÇÑ ±¹¼ÒºÎÀ§¹ÝÀÀÀ» °üÂûÇÏ°í ´ÙÀ½°ú °°Àº ÆÇÁ¤±âÁØ¿¡ ÀÇÇØ ÆÇÁ¤ÇÑ´Ù.
- ÆÇÁ¤±âÁØ
1) ¾ç¼º : µÎµå·¯±â ¾ç ¹ßÀûÀÇ Á÷°æÀÌ 20mm ÀÌ»ó ¶Ç´Â ÆØÁøÀÇ Á÷°æÀÌ 9mmÀÌ»ó
2) À½¼º : µÎµå·¯±â ¾ç ¹ßÀû, ÆØÁø ¸ðµÎ°¡ À§ÀÇ ¾ç¼ºÀÇ ÆÇÁ¤±âÁØ ¹Ì¸¸ ¶ÇÇÑ, ÁÖ»çÇÑ ±¹¼ÒÀÇ ¹ÝÀÀ À̿ܿ¡ Àü½Å¹ÝÀÀ[¾îÁö·¯¿ò, ¸¶ºñ°¨, ¿°¨, µÎÅë, º¯ÀÇ, ºÒ¾È, ºü¸¥¸Ç(ºó¸Æ), ±¸³»À̹°°¨ µî]À» È®ÀÎÇßÀ» °æ¿ì¿¡µµ ¾ç¼ºÀ¸·Î ÇÏ¸ç ´ëÁ¶¾×ÀÌ ¾ç¼ºÀ» ³ªÅ¸³»´Â °æ¿ì¿¡´Â ÆÇÁ¤ºÒ´ÉÀ¸·Î ÇÑ´Ù.
- óġ
1) ½ÃÇè¾×ÀÇ ÆÇÁ¤ÀÌ ¾ç¼ºÀÌ°í ´ëÁ¶¾×ÀÇ ÆÇÁ¤ÀÌ À½¼ºÀÏ °æ¿ì¿¡´Â ÀÌ ¾à¹° Åõ¿©¸¦ ½Ç½ÃÇÏÁö ¾Ê´Â´Ù.
2) ÆÇÁ¤ºÒ´ÉÀÎ °æ¿ì¿¡´Â ÀÌ ¾à¹°À» Åõ¿©ÇÏÁö ¾Ê°Å³ª, °ú¹Î¹ÝÀÀ¿¡ ÃæºÐÈ÷ ÁÖÀǸ¦ ±â¿ï¿© Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ ÀÇÇÏ¿© ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¼¼ÆÈ·Î½ºÆ÷¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
3) ÀúüÁßÃâ»ý¾Æ, ½Å»ý¾Æ, ¿µ¤ýÀ¯¾Æ, ¼Ò¾Æ(±ÙÀ°Áֻ翡 ÇÑÇÔ.)
4) ¸®µµÄ«ÀÎ µîÀÇ ¾Æ´Ò¸®µå°è ±¹¼Ò¸¶ÃëÁ¦¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ(±ÙÀ°Áֻ翡 ÇÑÇÔ.)
(Çdz»¹ÝÀÀ¿ë)
ÀÌ ¾à¹°¿¡ ÀÇÇÑ ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) ÀÌ ¾à ¶Ç´Â ¼¼Æè°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¿øÄ¢À̳ª ºÎµæÀÌ Åõ¿©ÇÒ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
2) Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
3) º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±âÁõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀΠȯÀÚ
4) ÁßÁõÀÇ ½ÅÀå¾Ö ȯÀÚ
5) °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾ç ȯÀÚ, °í·ÉÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ(ºñŸ¹Î K °áÇÌÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÑ´Ù.)
(Çdz»¹ÝÀÀ¿ë)
1) ´Ù¸¥ ¼¼Æè°è(¼¼ÆÈ·Î½ºÆ÷¸°°è ¹× ¼¼ÆÄ¸¶À̽Űè) ¶Ç´Â Æä´Ï½Ç¸°°è ¾à¹°¿¡ ´ëÇØ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀ» °¡Áø ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, ¾îÁö·¯¿ò, º¯ÀÇ, À̸í, ¹ßÇÑ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) °ú¹Î¹ÝÀÀ : ¶§¶§·Î ¹ßÁø, µÎµå·¯±â, È«¹Ý, °¡·Á¿ò, ¹ß¿, ¸²ÇÁÀý Á¾Ã¢, °üÀýÅë µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) ÇǺΠ: µå¹°°Ô ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº, µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
4) Ç÷¾×°è : ¶§¶§·Î ºóÇ÷, °ú¸³±¸ °¨¼Ò, ÀûÇ÷±¸ °¨¼Ò, È£»ê±¸ Áõ°¡, Ç÷¼ÒÆÇ °¨¼Ò µå¹°°Ô ¹üÇ÷±¸ °¨¼Ò, ¿ëÇ÷¼º ºóÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î, ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí, ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
5) °£Àå : ¶§¶§·Î AST, ALT, ALPÀÇ »ó½Â µå¹°°Ô Ȳ´Þ, LDH, ¥ã-GTP»ó½Â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ½ÅÀå : µå¹°°Ô ±Þ¼º ½ÅºÎÀü µîÀÇ ÁßÁõÀÇ ½ÅÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î °Ë»ç¸¦ ½Ç½ÃÇÏ´Â µî ÃæºÐÈ÷ °üÂûÇϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
7) ¼Òȱâ°è : µå¹°°Ô À§¸·¼º´ëÀå¿° µîÀÇ Ç÷º¯À» ¼ö¹ÝÇÏ´Â ÁßÁõÀÇ ´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ºó¹øÇÑ ¼³»ç°¡ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇÏ´Â µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶ÇÇÑ ¶§¶§·Î ±¸¿ª, ¼³»ç ¶ÇÇÑ µå¹°°Ô ±¸Åä, ½Ä¿åºÎÁø, º¹Åë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) È£Èí±â°è : µå¹°°Ô ¹ß¿, ±âħ, È£Èí°ï¶õ, ÈäºÎ X¼± ÀÌ»ó, È£»ê±¸ Áõ°¡ µîÀ» ¼ö¹ÝÇÏ´Â °£Áú¼º Æó·Å, È£»ê±¸¼º ÆóħÀ± µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÄÚ¸£Æ¼ÄÚÀ̵å Åõ¿© µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
9) ÁßÃ߽Űæ°è : ½ÅºÎÀü ȯÀÚ¿¡ ´ë·® Åõ¿© ½Ã °æ·Ã µîÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
10) ±Õ±³´ëÁõ : µå¹°°Ô ±¸³»¿°, ĵð´ÙÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ºñŸ¹Î °áÇÌÁõ : µå¹°°Ô ºñŸ¹Î K °áÇÌÁõ»ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâ µî), ºñŸ¹Î B±º °áÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿° µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
12) ±âŸ : µå¹°°Ô ¾îÁö·¯¿ò, µÎÅë, ±Çۨ, ¸¶ºñ°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
(Çdz»¹ÝÀÀ¿ë)
µå¹°°Ô ¼ï, ¾Æ³ªÇʶô½Ã¾ç Áõ»óÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇϰí, ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, ¾îÁö·¯¿ò, º¯ÀÇ, À̸í, ¹ßÇÑ, õ¸í, È£Èí°ï¶õ, ¸Æ°üºÎÁ¾, Àü½ÅÈ«Á¶, µÎµå·¯±â µîÀÇ ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
À¯»çÈÇÕ¹°(´Ù¸¥ ¼¼Æè°è Ç×»ý¹°Áú)°ú Ǫ·Î¼¼¹Ìµå µîÀÇ ÀÌ´¢Á¦¿Í º´¿ëÅõ¿© ½Ã ½Åµ¶¼ºÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: CEFOTIAM HYDROCHLORIDECERADON (CEFOTIAM HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ´ëÇ¥ÄÚµå |
8806447027301 |
| BIT ¾àÈ¿ºÐ·ù |
2¼¼´ë ¼¼ÆÈ·Î½ºÆ÷¸°°è (Cephalosporins; Second Generation)
|
| ATC ÄÚµå |
cefotiam / J01DC07
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
618 (ÁÖ·Î ±×¶÷¾ç¼º, À½¼º±Õ¿¡ ÀÛ¿ëÇÏ´Â °Í )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
¿¡½ºÄÉÀ̼¼Æ÷Ƽ¾Ï±ÙÁÖ0.5±×¶÷/ A18905961
Á¦Ç°±Ô°Ý: /Á¦Ç°¼ö·®: /Á¦Çü:
Æû¸ñ±âÁØÄÚµå: 199401275 /´ëÇ¥ÄÚµå: 8806447027301/Ç¥ÁØÄÚµå: 8806447027301
±¸¹ÙÄÚµå: -/ºñ°í:½Ä¾àûÇã°¡ ÃëÇÏ Ç°¸ñ(20071113)
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefotiam¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
|
| Pharmacology |
Cefotiam¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotiam works by inhibiting bacterial cell wall biosynthesis.
|
| Metabolism |
Cefotiam¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Cefotiam¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 40%
|
| Half-life |
Cefotiam¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Approximately 1 hour.
|
| Absorption |
Cefotiam¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection.
|
| Biotransformation |
Cefotiam¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Cefotiam¿¡ ´ëÇÑ Toxicity Á¤º¸ Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
|
| Drug Interactions |
Cefotiam¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefotiam¿¡ ´ëÇÑ Description Á¤º¸ One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms. [PubChem]
|
| Drug Category |
Cefotiam¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial Agents
|
| Smiles String Canonical |
Cefotiam¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCN1N=NN=C1SCC1=C(N2C(SC1)C(NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
|
| Smiles String Isomeric |
Cefotiam¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O
|
| InChI Identifier |
Cefotiam¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1/f/h21,30H,19H2
|
| Chemical IUPAC Name |
Cefotiam¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-01-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|